| | Variables | HCC on NAFLD (n = 41) | HCC on ALD (n = 41) | value |
| | Demographic and clinical | | Age in years, mean (SD) | 67.4 (10.7) | 65.6 (9.6) | 0.289 | | Male gender, n (%) | 26 (63.4%) | 37 (90.2%) | 0.051 | | Diabetes, n (%) | 16 (39.0%) | 13 (31.7%) | 0.488 | | Ischemic cardiomyopathy, n (%) | 4 (9.8%) | 1 (2.4%) | 0.166 | | Liver function | | CTP class A, n (%) | 33 (80.5%) | 35 (85.4%) | 0.557 | | CTP class B, n (%) | 8 (19.5%) | 6 (14.6%) | 0.557 | | CTP class C, n (%) | 0 (0.0%) | 0 (0.0%) | — | | Tumor characteristics | | Size | | Largest nodule (cm), mean (SD) | 6.3 (3.4) | 6.3 (3.7) | 0.256 | | <2 cm, n (%) | 4 (9.8%) | 3 (7.3%) | 0.639 | | 2.1–3 cm, n (%) | 2 (4.9%) | 4 (9.8%) | 0.396 | | 3.1–5 cm, n (%) | 12 (29.3%) | 14 (34.1%) | 0.635 | | >5 cm, n (%) | 23 (56.1%) | 20 (48.8%) | 0.507 | | Number of nodules | | 1, n (%) | 26 (63.4%) | 28 (68.3%) | 0.641 | | 2–3, n (%) | 6 (14.6%) | 6 (14.6%) | 1.000 | | >3, n (%) | 9 (22.0%) | 7 (17.1%) | 0.577 | | Infiltrative, n (%) | 0 (0.0%) | 0 (0.0%) | — | | Milan out, n (%) | 26 (63.4%) | 23 (56.1%) | 0.499 | | Macrovascular infiltration, n (%) | 8 (19.5%) | 6 (14.6%) | 0.557 | | Detection on surveillance, n (%) | 31 (75.6%) | 35 (85.4%) | 0.265 | | Initial treatment modality | | TACE, n (%) | 21 (51.2%) | 25 (61.0%) | 0.267 | | Surgical resection, n (%) | 11 (26.8%) | 6 (14.6%) | 0.173 | | RFA, n (%) | 0 (0.0%) | 1 (2.4%) | 0.314 | | Sorafenib, n (%) | 3 (7.3%) | 2 (4.9%) | 0.644 | | Best supportive care, n (%) | 6 (14.6%) | 7 (17.1%) | 0.762 |
|
|
